SABE belle BIOMALIFE® BAXTERBIOMA capsules, 60 ST

Name: SABE belle BIOMALIFE® BAXTERBIOMA capsules
Brand: SABE belle
SKU: RA8078266
Price: 31.5 EUR
Availability: LimitedAvailability

Image/color similar

SABE belle BIOMALIFE® BAXTERBIOMA capsules are a food supplement based on Limosilactobacillus reuteri Pylopass™.

€31.50

Content: 60 Stück (€0.53 / 1 Stück)

(May vary by country)

No longer available

Product number: RA8078266

Stück: 60

Manufacturer: SABE belle

Product information "SABE belle BIOMALIFE® BAXTERBIOMA capsules"

SABE belle BIOMALIFE® BAXTERBIOMA capsules are a food supplement based on Limosilactobacillus reuteri Pylopass™.

Helicobacter pylori

H. pylori is a bacterium found in the human stomach. It tolerates acidic pH levels very well as it produces ammonia. Furthermore, thanks to its spiral-shaped structure, it is able to penetrate the mucous layer and anchor itself to the inner stomach wall, where the acidity is lower. H. pylori infection is the most significant risk factor for chronic gastritis and a contributing factor to peptic ulcer disease (stomach ulcer), a severe and localised lesion of the mucous membrane of the digestive tract. Several factors contribute to this type of infection: a family history of the condition, cigarette smoking and severe stress.

Helicobacter pylori infection is diagnosed by means of:

Blood test
Stool test
Breath test

Typical symptoms of chronic gastritis include: pain in the upper abdomen, a feeling of fullness, nausea, vomiting, belching, loss of appetite, weight loss and indigestion (or poor digestion). Chronic gastritis can also be completely asymptomatic (around 20 per cent of cases).

Active ingredients

PYLOPASS™: Several clinical studies have shown that the eradication of H. pylori is more successful in patients who, in addition to pharmacological treatment, also take dietary supplements containing specific probiotic strains. One such strain is Pylopass™, a tyndallised strain of Limosilactobacillus reuteri. Pylopass™ binds specifically and selectively to H. pylori without affecting other bacterial strains in the gut microbiota. Each unit of L. reuteri binds 2–3 H. pylori bacteria. Thanks to this binding, H. pylori cannot adhere to the gastric mucosa and is excreted more easily.

In vivo studies demonstrate that Pylopass™ reduces the bacterial load of H. pylori, alleviates symptoms and increases the eradication rate of this bacterium in people undergoing pharmacological treatment.

Efficacy study

For the clinical trial by Parth (2021), 90 patients were divided into two groups. One group received triple eradication therapy with L. reuteri Pylopass™ for 14 days, whilst the other group received triple antibiotic therapy alone.
The following reduction in the most significant side effects of the eradication therapy was observed: nausea (60% vs. 86.67%, p=0.033), diarrhoea (36.6% vs. 50%, p=0.035), constipation (20% vs. 33.3%, p=0.026), and changes in taste (43.3% vs. 60%, p=0.047).
Patients treated with Pylopass™ in combination with antibiotic therapy also show statistically significant improvements in symptoms caused by the infection, such as stomach pain, heartburn, acid reflux, nausea, bloating and belching.
The eradication rate reported in the study rose from 66.67 per cent (group receiving triple antibiotic therapy) to 86.67 per cent (group receiving triple antibiotic therapy and Pylopass™).

Notes

Gluten-free
Naturally lactose-free
No sweeteners
No added sugar
No preservatives

• C. Holz, ‘Significant Reduction in Helicobacter pylori load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study’, Probiotics & Antimicrobial Proteins, 2014. • H. Mehling, “Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans”, Nutrients, 2013, 5, 3062–3073. • M.H. Emara, “Lactobacillus reuteri in the management of Helicobacter pylori infection in dyspeptic patients: a double-blind, placebo-controlled, randomised clinical trial”, Ther Adv Gastroenterol 2014, Vol 7(1) 4–13. • Lonza, “Pylopass™: A New Approach to H. pylori Control – Raw Material Presentation”, 2012. • Network Nutrition – IMCD, “Raw Material Brochure”. • K. Parth et al., “Efficacy of Lactobacillus reuteri Supplementation in the Eradication of H. pylori: A Comparison Study with Triple Drug Therapy”, JPRI, 33(52B): 151–159, 2021.

Dosage form

Tablets

Directions for use

Take 2 capsules daily with a large glass of water. Preferably take one capsule after breakfast and one capsule after dinner.
Notes: Suitable for children. Safe to use during pregnancy and whilst breastfeeding.

Ingredients

Ingredients: FILLERS: CELLULOSE, DICALCIUM PHOSPHATE; LIMOSILACTOBACILLUS REUTERI DSM 17648 (NON-LIVE CELLS, MALTODEXTRIN); COATING AGENT (CAPSULE): HYDROXYPROPYLMETHYLCELLULOSE; ANTI-CAKING AGENTS: MAGNESIUM SALTS OF FATTY ACIDS, SILICON DIOXIDE; COLOURING AGENT: CALCIUM CARBONATE.
Composition per daily dose (2 capsules): L. reuteri Pylopass™* 200 mg (equivalent to^2×10¹⁰ inactivated cells). *Pylopass™ is a trademark of Novozymes A/S, Denmark.

Gluten-free:	Yes
Lactose-free:	Yes
Piece:	60
Vegetarian:	Yes

0 of 0 reviews

Leave a review!

Share your experiences with other customers.

Your rating*

Excellent

Displayed Name

Your E-mail address

Title Please enter at least 5 characters.

Your review Please enter at least 40 characters.

Fields marked with asterisks (*) are required.

Cancel

Display reviews in current language only.

No reviews found. Share your insights with others.

Warnings - SABE belle BIOMALIFE® BAXTERBIOMA capsules

Instructions for use

Product recommendations for you

Our recommendation

SABE belle REFLUXcontrol sticks

SABE belle REFLUXcontrol Sticks are a medical device for oral use for the treatment of gastro-oesophageal reflux, heartburn, oesophagitis, irritable cough and belching due to gastric reflux.

Sofort verfügbar

Content: 20 Stück

€16.90*

Details

SABE belle REFLUXcontrol chewable tablets

SABE belle REFLUXcontrol chewable tablets are a medical product that reduces gastro-oesophageal reflux, relieves gastric acidity and protects the gastric mucosa.

Sofort verfügbar

Content: 24 Stück

€9.40*

Details

Customers also bought

5.02 %

SABE belle BIOMALIFE® BUTIRBIOMA enteric coated tablets

The SABE belle BIOMALIFE® BUTIRBIOMA tablets are a dietary supplement based on sodium butyrate. Each tablet contains 625 mg of modified-release sodium butyrate.

Sofort verfügbar

Content: 30 Stück

€23.46* €24.70*

5 %

SABE belle BIOMALIFE® PEABIOMA enteric coated tablets

SABE belle BIOMALIFE® PEABIOMA tablets are a food supplement based on palmitoylethanolamide. Each tablet contains 200 mg of micronised palmitoylethanolamide with modified release of the active ingredient.

Sofort verfügbar

Content: 30 Stück

€25.08* €26.40*

SABE belle BIOMALIFE® BIFIBIOMA capsules

SABE belle BIOMALIFE® BIFIBIOMA capsules are a dietary supplement containing probiotics based on Bifidobacterium longum BB536 and Bifidobacterium lactis HN019, in vegetable capsules.

Sofort verfügbar

Content: 30 Stück

€22.50*

SABE belle BIOMALIFE® LACTOBIOMA capsules

SABE belle BIOMALIFE® LACTOBIOMA capsules are a food supplement with probiotics based on Lactobacillus acidophilus NCFM® and Lactobacillus casei Lc-11, in vegetarian capsules.

Auf Bestellung

Content: 30 Stück

€22.50*

Details

5.03 %

SABE belle BIOMALIFE® BOULABIOMA stick bag

SABE belle BIOMALIFE® BOULABIOMA stick sachets are a food supplement based on Saccharomyces boulardii CNCM I-3799 Lynside®, Kluyveromyces marxianus ABB™ S8 and zinc.

Sofort verfügbar

Content: 14 Stück

€17.76* €18.70*

Rainbow Pharmacy DHEA 15 mg Capsules

DHEA 15 mg capsules from Regenbogen Apotheke are a dietary supplement containing dehydroepiandrosterone (DHEA), a hormone that is produced naturally by the body.

Auf Bestellung

Content: 30 Stück

from €20.00*

SABE belle BIOMALIFE® BAXTERBIOMA capsules, 60 ST

Dosage form

Directions for use

Ingredients

Instructions for use

We stay in touch!